search
Back to results

Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy Phase II (Afya 2 Phase2)

Primary Purpose

HIV (Human Immunodeficiency Virus)

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Tanzania
Study Type
Interventional
Intervention
Conditional Cash Transfer
Sponsored by
University of California, Berkeley
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for HIV (Human Immunodeficiency Virus) focused on measuring Antiretroviral Treatment Adherence, Conditional Cash Transfers, Tanzania, People Living With HIV, Behavioral Economics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Greater than or equal to 18 years of age
  • Living with HIV infection
  • Initiated on antiretroviral therapy less than or equal to 1 month prior to enrollment in the study
  • Have access to a mobile phone (ownership, shared ownership, or access to a trusted person's phone)
  • Do not intend to transfer to a different facility for HIV care within the following 12 months.

Exclusion Criteria:

-

Sites / Locations

  • Health for a Prosperous Nation (HPON)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Conditional Cash Transfer

Control

Arm Description

Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.

Participants attending control clinics will receive the standard of care.

Outcomes

Primary Outcome Measures

12-month Viral Suppression
the proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months after starting ART. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, WHO's threshold for virologic failure in LMICs) versus not on ART or viral failure (≥1000 copies/ml).

Secondary Outcome Measures

Appointment Attendance
The proportion of scheduled visits that were completed during the 0-12 month period
6-month Viral Suppression
the proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months after starting ART. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, WHO's threshold for virologic failure in LMICs) versus not on ART or viral failure (≥1000 copies/ml).
Proportion Virally Suppressed
• The proportion virally suppressed (<1000 copies/ml) of those PLHIV with a viral load result

Full Information

First Posted
December 11, 2019
Last Updated
August 18, 2022
Sponsor
University of California, Berkeley
Collaborators
Health for a Prosperous Nation, Rasello, Tanzania Ministry of Health, Community Development, Gender, Elderly and Children
search

1. Study Identification

Unique Protocol Identification Number
NCT04201353
Brief Title
Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy Phase II
Acronym
Afya 2 Phase2
Official Title
Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy, Phase II: Effectiveness Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
March 9, 2020 (Actual)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Berkeley
Collaborators
Health for a Prosperous Nation, Rasello, Tanzania Ministry of Health, Community Development, Gender, Elderly and Children

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This protocol describes a 2-arm cluster, randomized controlled trial designed to test the effectiveness of a conditional cash transfer on viral suppression at 12 months post-ART initiation among PHWHIV who have initiated ART within the past 30 days. Randomization will take place at the clinic level (HIV primary care clinics), and eligible participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. The study will take place at 32 clinics across four regions in Tanzania: Gaeta, Mwanza, Kagera and Shinyanga. The primary endpoint is viral suppression at 12 months, defined as the proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months after starting ART.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV (Human Immunodeficiency Virus)
Keywords
Antiretroviral Treatment Adherence, Conditional Cash Transfers, Tanzania, People Living With HIV, Behavioral Economics

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
2-arm cluster randomized control trial, with HIV primary care clinic as the unit of randomization
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Facility staff will not be blinded to intervention assignment. However, all other research staff will be blinded to intervention assignment. In addition, participants will not be told during the consent process that as part of the study there are intervention and control clinics. The rationale for this is to prevent patients transferring from intervention to control clinics if they find out that there are some clinics offering cash transfers to new ART clients. Large numbers of transferring patients will compromise the integrity of the study and will create an undue burden for facility staff at intervention clinics.
Allocation
Randomized
Enrollment
1984 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conditional Cash Transfer
Arm Type
Experimental
Arm Description
Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Participants attending control clinics will receive the standard of care.
Intervention Type
Behavioral
Intervention Name(s)
Conditional Cash Transfer
Intervention Description
The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (~$10) for up to 6 months conditional on visit attendance.
Primary Outcome Measure Information:
Title
12-month Viral Suppression
Description
the proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months after starting ART. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, WHO's threshold for virologic failure in LMICs) versus not on ART or viral failure (≥1000 copies/ml).
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Appointment Attendance
Description
The proportion of scheduled visits that were completed during the 0-12 month period
Time Frame
12 months
Title
6-month Viral Suppression
Description
the proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months after starting ART. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, WHO's threshold for virologic failure in LMICs) versus not on ART or viral failure (≥1000 copies/ml).
Time Frame
6 month
Title
Proportion Virally Suppressed
Description
• The proportion virally suppressed (<1000 copies/ml) of those PLHIV with a viral load result
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Greater than or equal to 18 years of age Living with HIV infection Initiated on antiretroviral therapy less than or equal to 1 month prior to enrollment in the study Have access to a mobile phone (ownership, shared ownership, or access to a trusted person's phone) Do not intend to transfer to a different facility for HIV care within the following 12 months. Exclusion Criteria: -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandra McCoy, PhD
Organizational Affiliation
University of California, Berkeley
Official's Role
Principal Investigator
Facility Information:
Facility Name
Health for a Prosperous Nation (HPON)
City
Dar Es Salaam
Country
Tanzania

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33228757
Citation
Packel L, Njau P, Fahey C, Ramadhani A, Dow WH, Jewell NP, McCoy S. Optimizing the efficiency and implementation of cash transfers to improve adherence to antiretroviral therapy: study protocol for a cluster randomized controlled trial. Trials. 2020 Nov 23;21(1):963. doi: 10.1186/s13063-020-04899-7.
Results Reference
derived

Learn more about this trial

Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy Phase II

We'll reach out to this number within 24 hrs